Metagenomi Therapeutics (MGX) Receivables - Net (2024 - 2025)
Metagenomi Therapeutics (MGX) posted quarterly Receivables - Net of $305000.0 for Q4 2025, down 72.27% year-over-year from $1.1 million in Q4 2024, and down 68.23% quarter-over-quarter from $960000.0 in Q3 2025.
Metagenomi Therapeutics (MGX) Receivables - Net (2024 - 2025) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Receivables - Net for 2 consecutive years, with $305000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables - Net fell 72.27% year-over-year to $305000.0; the TTM figure through Dec 2025 stood at $305000.0 (down 72.27% YoY), while the FY2025 annual figure was $305000.0, down 75.74% from the prior year.
- Receivables - Net eased to $305000.0 in Q4 2025 per MGX's latest filing, from $960000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $2.1 million in Q1 2024 and bottomed at $305000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 305,000.00 |
| Dec 31, 2025 | 305,000.00 |
| Sep 30, 2025 | 960,000.00 |
| Sep 30, 2025 | 960,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Mar 31, 2025 | 1.01 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 589,000.00 |
| Sep 30, 2024 | 589,000.00 |
| Jun 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 1.65 Mn |
| Mar 31, 2024 | 2.08 Mn |
| Mar 31, 2024 | 2.08 Mn |